SPL

.conf24: Splunk Introduces Advanced AI Enhancements for Observability, Security and IT Service Intelligence

Retrieved on: 
星期三, 六月 12, 2024

Splunk has expanded its AI capabilities with new generative AI assistants in Observability Cloud and Security, providing customers with improved IT visibility and enhanced proactive threat mitigation capabilities.

Key Points: 
  • Splunk has expanded its AI capabilities with new generative AI assistants in Observability Cloud and Security, providing customers with improved IT visibility and enhanced proactive threat mitigation capabilities.
  • Additionally, the company has made its Splunk AI Assistant for SPL generally available, helping customers derive insights from Splunk using natural language.
  • “AI is the cornerstone of Splunk’s strategy for driving enhancements with our industry-leading security and observability solutions,” said Hao Yang, VP, Head of AI at Splunk.
  • Splunk AI Assistant for SPL is now generally available to Splunk Cloud Platform customers with AWS globally.

USound & Luxshare-ICT Introduce Gemini 2.0 Dual Speaker Audio Module for TWS & IEMs

Retrieved on: 
星期四, 六月 6, 2024

USound , the leading global provider of MEMS speakers, announced today the availability of a new dual speaker audio module that was created in collaboration with the notable global designer and manufacturer Luxshare-ICT.

Key Points: 
  • USound , the leading global provider of MEMS speakers, announced today the availability of a new dual speaker audio module that was created in collaboration with the notable global designer and manufacturer Luxshare-ICT.
  • The development is now concluded and Gemini 2.0 UAM-C1102 dual speaker audio module is available for purchase.
  • (Photo: Business Wire)
    “We proudly announce the availability of the most advanced audio module for TWS and IEMs.
  • Designed to perform well above 20 kHz, it provides excellent audio performance that exceeds the strict requirements of TWS and IEMs’ manufacturers.

MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development

Retrieved on: 
星期三, 五月 22, 2024

, (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced it has entered into a strategic platform license (SPL) agreement with Legend Biotech, a global leader in cell therapy.

Key Points: 
  • , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced it has entered into a strategic platform license (SPL) agreement with Legend Biotech, a global leader in cell therapy.
  • Under the terms of the SPL, Legend Biotech obtains a non-exclusive worldwide license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform in connection with the research, clinical development and commercialization of cell-based therapeutical products (Licensed Products).
  • “We are looking forward to supporting Legend Biotech’s non-viral engineered cell therapy program as they expand their portfolio with new delivery modalities.
  • Legend Biotech is MaxCyte’s 28th clinical / commercial partnership overall, each partnership generates pre-commercial milestone revenue, the vast majority of which includes program-related revenue.

LIfT BioSciences Awarded Innovate UK Grant to Accelerate Product Development of New IMAN Cell Therapy Variants

Retrieved on: 
星期四, 五月 16, 2024

London, 16 May 2024 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company about to start clinical trials for its first-in-class allogeneic innate cell therapy, today announces it has been awarded a grant of over one million pounds from Innovate UK, the UK’s innovation agency.

Key Points: 
  • London, 16 May 2024 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company about to start clinical trials for its first-in-class allogeneic innate cell therapy, today announces it has been awarded a grant of over one million pounds from Innovate UK, the UK’s innovation agency.
  • SPL has developed and optimized cutting-edge tumour-bearing humanised mice which are essential for true modelling of IMAN safety and efficacy.
  • We are very excited to be working with LIfT on this project and are grateful for this funding from Innovate UK.”
    LIfT is developing its ground-breaking patented IMAN product as an allogeneic cell therapy for the treatment of solid tumours.
  • LIfT’s IMANs are generated using LIfT’s proprietary Neutrophil-based Leukocyte Infusion Therapy (N-LIfT) platform, with future iPSC-derived and gene engineered products in the pipeline.

SIFAS Festival of Arts 2024 to captivate audiences on April 27 and 28 at Esplanade - Theatres on the Bay

Retrieved on: 
星期一, 四月 22, 2024

Established in 1949, SIFAS has been a cornerstone of Indian cultural heritage in Singapore, fostering art and cultural appreciation through its diverse disciplines.

Key Points: 
  • Established in 1949, SIFAS has been a cornerstone of Indian cultural heritage in Singapore, fostering art and cultural appreciation through its diverse disciplines.
  • 2024 marks SIFAS' Diamond Jubilee, a significant milestone for the non-profit organisation committed to nurturing talent and promoting Indian fine arts in the region.
  • The SIFAS Festival OF Arts 2024, in its 20th year, is an iconic event in SIFAS' cultural calendar, which celebrates the institution's legacy as the heart and hub of Indian arts in Singapore.
  • Event Details are as follows:
    Venue: Esplanade - Theatres on the Bay, 1 Esplanade Drive, Singapore 038981

MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance

Retrieved on: 
星期二, 五月 7, 2024

Cell therapy revenue for the first quarter of 2024 was $6.4 million, compared to $6.0 million in the first quarter of 2023, representing an increase of 7%.

Key Points: 
  • Cell therapy revenue for the first quarter of 2024 was $6.4 million, compared to $6.0 million in the first quarter of 2023, representing an increase of 7%.
  • Drug discovery revenue for the first quarter of 2024 was $1.8 million, compared to $1.8 million in the first quarter of 2023.
  • SPL Program-related revenue was $3.2 million in the first quarter of 2024, as compared to $0.8 million in the first quarter of 2023.
  • MaxCyte affirms 2024 revenue guidance for core business revenue and is increasing SPL Program-related revenue guidance.

Cheniere Partners Announces Pricing of $1.2 Billion Senior Notes due 2034

Retrieved on: 
星期三, 五月 8, 2024

Cheniere Energy Partners, L.P. (“Cheniere Partners”) (NYSE: CQP) announced today that it has priced its previously announced offering of Senior Notes due 2034 (the “CQP 2034 Notes”).

Key Points: 
  • Cheniere Energy Partners, L.P. (“Cheniere Partners”) (NYSE: CQP) announced today that it has priced its previously announced offering of Senior Notes due 2034 (the “CQP 2034 Notes”).
  • The CQP 2034 Notes will bear interest at a rate of 5.750% per annum and will mature on August 15, 2034.
  • The CQP 2034 Notes will be issued at a price equal to 99.820% of par.
  • The CQP 2034 Notes will rank pari passu in right of payment with the existing senior notes at Cheniere Partners, including the senior notes due 2029, the senior notes due 2031, the senior notes due 2032 and the senior notes due 2033.

Cheniere Partners Announces Offering of Senior Notes due 2034

Retrieved on: 
星期三, 五月 8, 2024

Cheniere Energy Partners, L.P. (“Cheniere Partners”) (NYSE: CQP) announced today that it intends to offer, subject to market and other conditions, Senior Notes due 2034 (the “CQP 2034 Notes”).

Key Points: 
  • Cheniere Energy Partners, L.P. (“Cheniere Partners”) (NYSE: CQP) announced today that it intends to offer, subject to market and other conditions, Senior Notes due 2034 (the “CQP 2034 Notes”).
  • Cheniere Partners intends to contribute the proceeds from the offering to its subsidiary, Sabine Pass Liquefaction, LLC, to be used to redeem a portion of the outstanding aggregate principal amount of its senior secured notes due 2025 (the “SPL 2025 Notes”).
  • This press release does not constitute an offer to purchase or a solicitation of an offer to sell the SPL 2025 Notes or a notice of redemption under the indenture governing the SPL 2025 Notes.
  • The CQP 2034 Notes will rank pari passu in right of payment with existing senior notes at Cheniere Partners, including the senior notes due 2029, the senior notes due 2031, the senior notes due 2032 and the senior notes due 2033.

Cheniere Partners Reports First Quarter 2024 Results and Reconfirms Full Year 2024 Distribution Guidance

Retrieved on: 
星期五, 五月 3, 2024

Adjusted EBITDA1 decreased by approximately $26 million during the three months ended March 31, 2024, as compared to the corresponding 2023 period.

Key Points: 
  • Adjusted EBITDA1 decreased by approximately $26 million during the three months ended March 31, 2024, as compared to the corresponding 2023 period.
  • The common unit distribution and the related general partner distribution will be paid on May 15, 2024.
  • Cheniere Energy, Inc. will host a conference call to discuss its financial and operating results for first quarter 2024 on Friday, May 3, 2024, at 11 a.m. Eastern time / 10 a.m. Central time.
  • The call and accompanying slide presentation will include financial and operating results or other information regarding Cheniere Partners.

Godox Launches Magic XT1: A Next-Gen 2.4GHz Wireless Microphone System Make You Believe in Magic

Retrieved on: 
星期二, 四月 30, 2024

SHENZHEN, China, April 30, 2024 /PRNewswire/ -- Godox, a lighting equipment expert and innovator of gears for photographers and videographers, proudly presents a brand new 2.4GHz wireless microphone system Magic XT1.

Key Points: 
  • SHENZHEN, China, April 30, 2024 /PRNewswire/ -- Godox, a lighting equipment expert and innovator of gears for photographers and videographers, proudly presents a brand new 2.4GHz wireless microphone system Magic XT1.
  • It is a Next-Gen 2.4GHz wireless microphone system revolutionized with a charging-in-RX design that breaks away from the traditional charging case.
  • Featuring an OLED touchscreen, safety track backup & superior audio performance, it offers you a premium experience like never before.
  • Crafted with top-notch acoustic technology, Magic XT1 boasts premium microphone components delivering impressive 48kHz/24bit Hi-Res audio with a 70dB SNR and a Max.